• Palvella Therapeutics began dosing first patients in LOTU, a Phase 2 trial testing topical QTORIN rapamycin gel for clinically significant angiokeratomas, a rare condition with no FDA-approved treatments.
• Study reads out in second half of 2027, with no results reported yet.
• Trial aims to show safety and clinical improvement versus baseline, targeting symptoms that drive bleeding risk, infection risk, and quality-of-life burden.
• Program carries FDA Fast Track status, supporting a faster development path if Phase 2 data are positive.
• Management framed angiokeratomas as a meaningful commercial opportunity, citing more than 50,000 diagnosed patients in US.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Palvella Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605040730PRIMZONEFULLFEED9712111) on May 04, 2026, and is solely responsible for the information contained therein.